$INCY

CAGNONI PABLO J sold $1.9M of INCY

CAGNONI PABLO J (President, Global Head of R&D) sold 15,888 shares of INCYTE CORP (INCY) at $119.70 ($1.90M total) on 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAGNONI PABLO J
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosed sale is pre-arranged under Rule 10b5-1, which generally lowers the probability that the transaction reflects new, nonpublic negative information.

02

Market read

Traders may briefly reassess sentiment around Incyte, but the 10b5-1 structure makes this more of a routine disclosure than a catalyst.

03

What to watch

The article does not state whether the sale was for diversification, tax, or compensation-related liquidity needs; without that context, signal strength is limited.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-04, disclosing a 2026-07-31 insider sale.

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an officer (President, Global Head of R&D).

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows R&D President Pablo J Cagnoni sold 15,888 shares at $119.70 on 2026-07-31 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale with an explicit 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with internal expectations of weaker near-term performance, so traders may watch for follow-on disclosures.

Key entities

  • INCY

    Incyte Corp, the company whose insider transaction is disclosed.

  • Pablo J Cagnoni

    President, Global Head of R&D, who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.